Abstract
Efficacious new drugs to treat hepatitis C virus infection offer the potential to halt this epidemic. But their exorbitant cost may prove prohibitive for most patients in need. Strong patient and government advocacy will be necessary to ensure that accessibility to treatments is a right, not a privilege.
MeSH terms
-
Antiviral Agents / economics*
-
Antiviral Agents / therapeutic use
-
Drug Costs
-
Drug Therapy, Combination
-
Hepatitis C, Chronic / drug therapy*
-
Heterocyclic Compounds, 3-Ring / economics
-
Heterocyclic Compounds, 3-Ring / therapeutic use
-
Humans
-
Interferons / therapeutic use
-
Ribavirin / therapeutic use
-
Simeprevir
-
Sofosbuvir
-
Sulfonamides / economics
-
Sulfonamides / therapeutic use
-
Uridine Monophosphate / analogs & derivatives
-
Uridine Monophosphate / economics
-
Uridine Monophosphate / therapeutic use
Substances
-
Antiviral Agents
-
Heterocyclic Compounds, 3-Ring
-
Sulfonamides
-
Ribavirin
-
Interferons
-
Simeprevir
-
Uridine Monophosphate
-
Sofosbuvir